Forge achieves carb-x milestone to advance its lpxc antibiotic to treat infections caused by the world’s deadliest ‘superbugs’

-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San Diego, California, August 1, 2018 – Forge Therapeutics, [...]

2018-07-31T23:33:37-07:00August 1st, 2018|

ASM Microbe 2018 LB19 “Improved Gram-negative Antibacterial Activity Upon Combination of LpxC Inhibitor FG-944 and RNA Polymerase Inhibitors (Rifampin or APY281)

2018-06-12T15:43:14-07:00June 12th, 2018|

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David [...]

2018-04-09T06:55:22-07:00April 9th, 2018|
Load More Posts